These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34972256)

  • 1. Longitudinal amyloid cognitive composite in preclinical Alzheimer's disease.
    Kim YJ; Hahn A; Park YH; Na DL; Chin J; Seo SW
    Eur J Neurol; 2022 Apr; 29(4):980-989. PubMed ID: 34972256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
    Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
    J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of a Cognitive Composite for Preclinical Alzheimer's Disease in Korean Older Adults.
    Kim M; Yi D; Byun MS; Ahn H; Jung JH; Kong N; Chang Y; Choi H; Choi J; Kim K; Jung G; Lee DY;
    J Alzheimers Dis; 2023; 96(2):633-641. PubMed ID: 37807780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: the CoSCo prospective cohort study.
    Hong YJ; Ho S; Jeong JH; Park KH; Kim S; Wang MJ; Choi SH; Yang DW;
    Alzheimers Res Ther; 2023 Aug; 15(1):132. PubMed ID: 37550761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Social Engagement and Amyloid-β-Related Cognitive Decline in Cognitively Normal Older Adults.
    Biddle KD; d'Oleire Uquillas F; Jacobs HIL; Zide B; Kirn DR; Rentz DM; Johnson KA; Sperling RA; Donovan NJ
    Am J Geriatr Psychiatry; 2019 Nov; 27(11):1247-1256. PubMed ID: 31248770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
    Donohue MC; Sperling RA; Salmon DP; Rentz DM; Raman R; Thomas RG; Weiner M; Aisen PS; ; ;
    JAMA Neurol; 2014 Aug; 71(8):961-70. PubMed ID: 24886908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.
    Mormino EC; Papp KV; Rentz DM; Donohue MC; Amariglio R; Quiroz YT; Chhatwal J; Marshall GA; Donovan N; Jackson J; Gatchel JR; Hanseeuw BJ; Schultz AP; Aisen PS; Johnson KA; Sperling RA
    Alzheimers Dement; 2017 Sep; 13(9):1004-1012. PubMed ID: 28253478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining clinically meaningful decline in preclinical Alzheimer disease.
    Insel PS; Weiner M; Mackin RS; Mormino E; Lim YY; Stomrud E; Palmqvist S; Masters CL; Maruff PT; Hansson O; Mattsson N
    Neurology; 2019 Jul; 93(4):e322-e333. PubMed ID: 31289148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
    Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
    JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation.
    Racine AM; Adluru N; Alexander AL; Christian BT; Okonkwo OC; Oh J; Cleary CA; Birdsill A; Hillmer AT; Murali D; Barnhart TE; Gallagher CL; Carlsson CM; Rowley HA; Dowling NM; Asthana S; Sager MA; Bendlin BB; Johnson SC
    Neuroimage Clin; 2014; 4():604-14. PubMed ID: 24936411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.
    Donohue MC; Sperling RA; Petersen R; Sun CK; Weiner MW; Aisen PS;
    JAMA; 2017 Jun; 317(22):2305-2316. PubMed ID: 28609533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study.
    Rabin JS; Schultz AP; Hedden T; Viswanathan A; Marshall GA; Kilpatrick E; Klein H; Buckley RF; Yang HS; Properzi M; Rao V; Kirn DR; Papp KV; Rentz DM; Johnson KA; Sperling RA; Chhatwal JP
    JAMA Neurol; 2018 Sep; 75(9):1124-1131. PubMed ID: 29799986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of β-Amyloid and Vascular Risk on Longitudinal Patterns of Brain Atrophy.
    Rabin JS; Pruzin J; Scott M; Yang HS; Hampton O; Hsieh S; Schultz AP; Buckley RF; Hedden T; Rentz D; Johnson KA; Sperling RA; Chhatwal JP
    Neurology; 2022 Jul; 99(3):e270-e280. PubMed ID: 35473760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.